U.S. FDA approves Bristol-Myers immunotherapy for lung cancer

March 4, 2015 7:13 PM

2 0

(Reuters) - U.S. health regulators on Wednesday swiftly approved a Bristol-Myers Squibb Co drug that helps the immune system fight the most common form of lung cancer, sending the company's shares up more than 5 percent to a multi-year high.

The eagerly anticipated Food and Drug Administration approval of the drug known as Opdivo came only about three months after Bristol provided trial results showing that the medicine extended survival in non-small cell lung cancer (NSCLC), one of the biggest markets in oncology. The decision also cam...

Also read: EU: on track to meet 2020 targets on renewables, emissions

Read more

To category page

Loading...